Graft-versus-host disease: why have we not made more progress? - Wikidata - wikimedia - TriplyDB

Graft-versus-host disease: why have we not made more progress?

Graft-versus-host disease: why have we not made more progress?

http://www.wikidata.org/entity/Q27012940

about

Biomaterials and host versus graft response: a short review Graft-versus-host disease affecting oral cavity. A review Extracorporeal photopheresis for graft-versus-host disease: the role of patient, transplant, and classification criteria and hematologic values on outcome-results from a large single-center study.Hsp90 inhibition ameliorates CD4(+) T cell-mediated acute Graft versus Host disease in mice.Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.Peri-Transplant RBC Transfusion is Associated with Increased Risk of GvHD after Allogeneic Stem Cell Transplantation.Cataract after allogeneic hematopoietic stem cell transplantation in childhood.Comparison of the Efficacy of Topical Triamcinolone in Orabase and Curcumin in Orabase in Oral Graft-Versus-Host Disease.

P2860

Q26764759-F73559BE-448E-4008-90C9-EDD02EA7BC53 Q27004303-10AE984B-FC6B-46FC-B087-CE05900A57AF Q35495340-349D0A14-2E3F-4EDA-BC37-9244546F3336 Q39096609-E0A1A95E-3DDF-455E-81A1-B8EB9CD14F78 Q40085103-4E4CDBB6-15B7-4515-B368-CCBF040B804F Q47200642-6FB43164-940E-4D3F-B965-873B5CF02037 Q50989345-50FBC0EF-87CC-4475-88FE-A09B23830885 Q55397395-88699D01-0F4C-4FBF-B101-3263989F376E

P2860

Graft-versus-host disease: why have we not made more progress?

http://www.wikidata.org/entity/Q27012940

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Graft-versus-host disease: why have we not made more progress?

@ast

Graft-versus-host disease: why have we not made more progress?

@en

Graft-versus-host disease: why have we not made more progress?

@nl

type

label

Graft-versus-host disease: why have we not made more progress?

@ast

Graft-versus-host disease: why have we not made more progress?

@en

Graft-versus-host disease: why have we not made more progress?

@nl

prefLabel

Graft-versus-host disease: why have we not made more progress?

@ast

Graft-versus-host disease: why have we not made more progress?

@en

Graft-versus-host disease: why have we not made more progress?

@nl

P1433

Q27012940-2F23A0E0-A157-43B1-8843-8D7A4EA69A0B

P1476

Q27012940-9744AC88-5068-40C9-8765-CD7CFB975A95

P2093

Q27012940-4E43509B-A5BE-426B-8E1C-97BC70A63609

Q27012940-7FF0D938-F7A6-4A42-8B86-47381B1098C7

P2860

Q27012940-073AA389-044F-4612-9DAB-B12160B17CAE

Q27012940-13526715-B458-47FD-AFEF-1C55AD123458

Q27012940-1AD64928-1EDA-4D9C-A408-AA4E6CCEE125

Q27012940-23841904-2B67-4DA4-8B27-5F0B3F5EC311

Q27012940-243A7733-1718-40E2-973B-EAB27215465F

Q27012940-2FB3BD85-3D4D-425E-A0A2-849D7C0C937D

Q27012940-375B0248-AE00-475C-AB3F-ADDF04D0EA6D

Q27012940-3BCADD38-87C0-4ED8-B493-98C01752DB26

Q27012940-3C59330B-FB50-49BC-8658-EB5D0FFF2FFF

Q27012940-3D197DAB-11DC-42B5-A8B8-E0D87FE1AB0D

P304

Q27012940-D623E183-B025-427A-922B-31453DBAE439

P31

Q27012940-CA92111E-94B0-4D31-9F53-D5C87D5C3078

P3181

Q27012940-3EB2D442-B924-4648-80E0-36D18741DA7A

P356

Q27012940-8ECC3EF8-81B3-4449-9991-40B1147EBB2A

P407

Q27012940-196FCF2A-319C-4953-83EE-E76C27896C2F

P433

Q27012940-EAF4CC17-343C-4E46-AC5C-511311857075

P478

Q27012940-77E12E06-4001-45CD-89FA-F0F887C2D232

P577

Q27012940-D1E18761-9690-43BA-BDFD-8E12E8AF9262

P698

Q27012940-F53C183E-8008-45CC-890A-8A65B4E64756

P932

Q27012940-235D6778-1446-4CE8-B495-AADDED0C67F4

P3181

P356

MOH.0000000000000026

P1433

Current Opinion in Hematology

P1476

Graft-versus-host disease: why have we not made more progress?

@en

P2093

Samantha M. Jaglowski

http://www.w3.org/2001/XMLSchema#string

Steven M. Devine

http://www.w3.org/2001/XMLSchema#string

P2860

Novel treatment concepts for graft-versus-host disease

Dendritic cells and the control of immunity

Thalidomide for treatment of patients with chronic graft-versus-host disease.

Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.

Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.

Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.

Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation

Advances in graft-versus-host disease biology and therapy.

P304

141-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3052569

http://www.w3.org/2001/XMLSchema#string

P356

10.1097/MOH.0000000000000026

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24468835

http://www.w3.org/2001/XMLSchema#string

P932

4131840

http://www.w3.org/2001/XMLSchema#string